BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 11046127)

  • 21. Correlation between omeprazole hydroxylase and CYP2C19 genotype in North Indians.
    Lamba JK; Dhiman RK; Singh R; Kohli KK
    Eur J Clin Pharmacol; 2001 Nov; 57(9):649-52. PubMed ID: 11791894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes.
    Katsuki H; Hamada A; Nakamura C; Arimori K; Nakano M
    Eur J Clin Pharmacol; 2001 Dec; 57(10):709-15. PubMed ID: 11829200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of CYP2C19 in stereoselective hydroxylation of mephobarbital by human liver microsomes.
    Kobayashi K; Kogo M; Tani M; Shimada N; Ishizaki T; Numazawa S; Yoshida T; Yamamoto T; Kuroiwa Y; Chiba K
    Drug Metab Dispos; 2001 Jan; 29(1):36-40. PubMed ID: 11124227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1'-hydroxylation.
    Emoto C; Iwasaki K
    Xenobiotica; 2007 Jun; 37(6):592-603. PubMed ID: 17614006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
    Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
    Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.
    Kimura M; Ieiri I; Wada Y; Mamiya K; Urae A; Iimori E; Sakai T; Otsubo K; Higuchi S
    Br J Clin Pharmacol; 1999 Jan; 47(1):115-9. PubMed ID: 10073749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A).
    Yasumori T; Chen L; Nagata K; Yamazoe Y; Kato R
    J Pharmacol Exp Ther; 1993 Jan; 264(1):89-94. PubMed ID: 8423554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19.
    Hirani VN; Raucy JL; Lasker JM
    Drug Metab Dispos; 2004 Dec; 32(12):1462-7. PubMed ID: 15448116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
    Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
    Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.
    VandenBranden M; Ring BJ; Binkley SN; Wrighton SA
    Pharmacogenetics; 1996 Feb; 6(1):81-91. PubMed ID: 8845864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
    Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes.
    Laine K; Yasar U; Widén J; Tybring G
    Pharmacol Toxicol; 2003 Aug; 93(2):77-81. PubMed ID: 12899669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
    Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
    Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes.
    Lu AH; Shu Y; Huang SL; Wang W; Ou-Yang DS; Zhou HH
    Acta Pharmacol Sin; 2000 Aug; 21(8):747-52. PubMed ID: 11501186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase.
    Zhou HH
    Clin Chim Acta; 2001 Nov; 313(1-2):203-8. PubMed ID: 11694260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes.
    Kobayashi K; Chiba K; Yagi T; Shimada N; Taniguchi T; Horie T; Tani M; Yamamoto T; Ishizaki T; Kuroiwa Y
    J Pharmacol Exp Ther; 1997 Feb; 280(2):927-33. PubMed ID: 9023308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.
    Abelö A; Andersson TB; Antonsson M; Naudot AK; Skånberg I; Weidolf L
    Drug Metab Dispos; 2000 Aug; 28(8):966-72. PubMed ID: 10901708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
    Gentile DM; Verhoeven CH; Shimada T; Back DJ
    J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
    Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
    Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency.
    Meier UT; Meyer UA
    Biochemistry; 1987 Dec; 26(25):8466-74. PubMed ID: 3442670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.